AI Article Synopsis
- tDCS shows variable antidepressant effects with some patients responding better than others, highlighting the need for more individualized treatment approaches.
- The study compared the effectiveness of tDCS, escitalopram (a common antidepressant), and placebo over 10 weeks, identifying specific symptom clusters like "core depressive" and "sleep/insomnia."
- Results indicated that escitalopram outperformed tDCS for core depressive symptoms, while tDCS was more effective for sleep issues, suggesting that both treatments have unique benefits depending on the symptom cluster.
Article Abstract
Background: Transcranial direct current stimulation (tDCS) presents small antidepressant efficacy at group level and considerable inter-individual variability of response. Its heterogeneous effects bring the need to investigate whether specific groups of patients submitted to tDCS could present comparable or larger improvement compared to pharmacotherapy. Aggregate measurements might be insufficient to address its effects.
Objective: /Hypothesis: To determine the efficacy of tDCS, compared to pharmacotherapy and placebo, in depressive symptom clusters.
Methods: Data from ELECT-TDCS (Escitalopram versus Electrical Direct-Current Therapy for Treating Depression Clinical Study, ClinicalTrials.gov, NCT01894815), in which antidepressant-free, depressed patients were randomized to receive 22 bifrontal tDCS (2 mA, 30 min) sessions (n = 94), escitalopram 20 mg/day (n = 91), or placebo (n = 60) over 10 weeks. Agglomerative hierarchical clustering identified "sleep/insomnia", "core depressive", "guilt/anxiety", and "atypical" clusters that were the dependent measure. Trajectories were estimated using linear mixed regression models. Effect sizes are expressed in raw HAM-D units. P-values were adjusted for multiple comparisons.
Results: For core depressive symptoms, escitalopram was superior to tDCS (ES = -0.56; CI = -0.94 to -0.17, p = .009), which was superior to placebo (ES = 0.49; CI = 0.06 to 0.92, p = .042). TDCS but not escitalopram was superior to placebo in sleep/insomnia symptoms (ES = 0.87; CI = 0.22 to 1.52, p = .015). Escitalopram but not tDCS was superior to placebo in guilt/anxiety symptoms (ES = 1.66; CI = 0.58 to 2.75, p = .006). No active intervention was superior to placebo for atypical symptoms.
Conclusions: Pharmacotherapy and non-invasive brain stimulation produce distinct effects in depressive symptoms. TDCS or escitalopram could be chosen according to specific clusters of symptoms for a bigger response.
Trial Registration: ClinicalTrials.gov, NCT01894815.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.brs.2021.05.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!